Machine signal
Active cluster sell — 4 distinct insiders, $6.2M, window ends Nov 2, 2026.
Figures computed from official regulatory filings — .
Analysttarget 62.46 USD (+99%) · consensus 4.93/5 · 14 buy · 0 hold · 0 sell
Ownershipinsiders 1.76% · institutions 111.89% · short 13.3% of float · 8.84d to cover
In USD · as of Nov 16, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Maze Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Market information source · Nov 16, 2026
SEC company identity · Nov 16, 2026
Purchases and sales · full history
101 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Coloma Jason V | Sell | $799.4K | SEC | ||
| Coloma Jason V | Sell | $10.4K | SEC | ||
| Coloma Jason V | Sell | $166K | SEC | ||
| Coloma Jason V | Sell | $68K | SEC | ||
| Dandekar Atul | Exercise | $8.9K | SEC | ||
| Dandekar Atul | Sell | $240.5K | SEC | ||
| Dandekar Atul | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Dandekar Atul | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Dandekar Atul | Exercise | $69.2K | SEC | ||
| Bernstein Harold | Sell | $434.7K | SEC | ||
| Bernstein Harold | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Coloma Jason V | Sell | $70.1K | SEC | ||
| Bernstein Harold | Exercise | $168.2K | SEC | ||
| Coloma Jason V | Sell | $862.2K | SEC | ||
| Dandekar Atul | Sell | $202.9K | SEC | ||
| Dandekar Atul | Exercise | $78.2K | SEC | ||
| Dandekar Atul | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Bernstein Harold | Sell | $254.5K | SEC | ||
| Courtney Phillips | Sell | $567.2 | SEC | ||
| Coloma Jason V | Sell | $259.9K | SEC | ||
| Bernstein Harold | Sell | $133.4K | SEC | ||
| Dandekar Atul | Sell | $929.2 | SEC | ||
| Dandekar Atul | Sell | $83.4K | SEC | ||
| Courtney Phillips | Sell | $6.6K | SEC | ||
| Coloma Jason V | Sell | $3.3K | SEC |